Cost Utility Analysis of Fluticasone Exhalation Delivery System Versus Budesonide Nasal Irrigation for Chronic Rhinosinusitis With Nasal Polyps
International Forum of Allergy & Rhinology · 2026
DOI: 10.1002/alr.70121 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Forum of Allergy & Rhinology, 2026. Verfasst von Daniel Xiao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology-Head and Neck Surgery, McGovern Medical School of The University of Texas Health Science Center at Houston, Houston…. Hauptthemen laut MEDLINE: Rhinosinusitis, Fluticasone, Nasal Polyps, Budesonide. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Chronic rhinosinusitis with nasal polyps (CRSwNP) is managed after sinus surgery with topical corticosteroids. Given limited distribution of nasal steroid sprays, patients have the option of either steroid nasal irrigation (SNI) or exhalation delivery system with fluticasone (EDS‐FLU). This study evaluates the cost‐effectiveness of EDS‐FLU compared to SNI for CRSwNP.
Methods
A cohort‐style Markov decision‐tree economic model with a 33‐year time horizon was developed in TreeAgePro. Because EDS‐FLU is not currently covered by Medicare, costs of medications were estimated using retail pricing. A willingness‐to‐pay threshold of $50,000/quality adjusted life year (QALY) was used to determine cost‐effectiveness. One‐way and probabilistic sensitivity analysis was conducted using 10,000 Monte Carlo simulations.
Results
EDS‐FLU had an incremental benefit of 0.41 QALYs compared to SNI. In base case analysis, EDS‐FLU costs $140,966.63 after the study period, whereas SNI costs $40,817.50. With an ICER of $244,185.37/QALY, SNI is the more cost‐effective strategy. Probabilistic sensitivity analysis reported SNI as the cost‐effective strategy in 98.50% of simulations.
Conclusions
Compared to EDS‐FLU, SNI is the cost‐effective strategy for treating CRSwNP following FESS. Changes in drug pricing and improvements in patient selection may cause adjustments in the most cost‐effective strategy for CRSwNP management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology-Head and Neck Surgery, McGovern Medical School of The University of Texas Health Science Center at Houston, Houston, Texas, USA.
- Center for Immunology and Autoimmune Diseases, The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, McGovern Medical School of The University of Texas Health Science Center at Houst…
ORCID-Profile: Daniel Xiao, William C Yao, Amber U Luong
Zitieren
APA
Xiao, D., Citardi, M. J., Yao, W. C., & Luong, A. U. (2026). Cost Utility Analysis of Fluticasone Exhalation Delivery System Versus Budesonide Nasal Irrigation for Chronic Rhinosinusitis With Nasal Polyps. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.70121
Vancouver
Xiao D, Citardi MJ, Yao WC, Luong AU. Cost Utility Analysis of Fluticasone Exhalation Delivery System Versus Budesonide Nasal Irrigation for Chronic Rhinosinusitis With Nasal Polyps. International Forum of Allergy & Rhinology. 2026. doi:10.1002/alr.70121
BibTeX
@article{Xiao2026,
author = {Xiao, Daniel and Citardi, Martin J and Yao, William C and Luong, Amber U},
title = {Cost Utility Analysis of Fluticasone Exhalation Delivery System Versus Budesonide Nasal Irrigation for Chronic Rhinosinusitis With Nasal Polyps},
journal = {International Forum of Allergy & Rhinology},
year = {2026},
doi = {10.1002/alr.70121}
}
EUVIMED